Geriatrik Prostat Kanseri Hastalarına Yaklaşım

Institute NC. SEERCancer Stat Facts: prostate cancer. 2018.

Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. European journal of cancer. 2015;51(9):1164-87.

Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. European journal of cancer. 2019;116:116-36.

Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU International. 2011;107(4):576-84.

Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical reviews in oncology/hematology. 2010;73(1):68-91.

Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU International. 2010;106(4):462-9.

Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncology. 2014;15(9):e404-14.

Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. Public Library of Science one. 2014;9(12):e115060.

Droz JP, Albrand G, Gillessen S, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. European Urology. 2017;72(4):521-31.

Droz JP, Boyle H, Albrand G, et al. Role of Geriatric Oncologists in Optimizing Care of Urological Oncology Patients. European Urology Focus. 2017;3(4-5):385-94.

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal of clinical oncology. 1982;5(6):649-55.

Wedding U, Ködding D, Pientka L, et al. Physicians’ judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Critical reviews in oncology/hematology. 2007;64(1):1-9.

Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. Journal of clinical oncology. 2014;32(24):2595-603.

Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Annals of oncology. 2015;26(2):288-300.

Conford P. TD, van der Bergh R.C.N., Eberli D., et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. 2025. Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/.

Şen V, Yıldız A, Bozkurt O, et al. Turkish Linguistic Validation of the Geriatric 8 Screening Tool. Bulletin of Urooncology. 2021;20(3):133-7.

Tsoi KK, Chan JY, Hirai HW, et al. Cognitive Tests to Detect Dementia: A Systematic Review and Meta-analysis. JAMA internal medicine. 2015;175(9):1450-8.

Borson S, Scanlan JM, Chen P, et al. The Mini‐Cog as a screen for dementia: validation in a population‐based sample. Journal of the American Geriatrics Society. 2003;51(10):1451-4.

Solomon DH. Geriatric assessment: methods for clinical decision making. Journal of the American Medical Association. 1988;259(16):2450-2.

Reuben DB, Fishman LK, McNabney M, et al. Looking inside the black box of comprehensive geriatric assessment: a classification system for problems, recommendations, and implementation strategies. Journal of the American Geriatrics Society. 1996;44(7):835-8.

Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. The Cochrane database of systematic reviews. 2017;9(9):CD006211.

Puts MTE, Sattar S, Kulik M, et al. A randomized phase II trial of geriatric assessment and management for older cancer patients. Supportive care in cancer. 2018;26(1):109-17.

Schmidt H, Boese S, Lampe K, et al. Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). Journal of geriatric oncology. 2017;8(4):262-70.

Magnuson A, Lemelman T, Pandya C, et al. Geriatric assessment with management intervention in older adults with cancer: a randomized pilot study. Supportive care in cancer. 2018;26(2):605-13.

Kalsi T, Babic-Illman G, Ross P, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. British journal of cancer. 2015;112(9):1435-44.

McCleary NJ, Wigler D, Berry D, et al. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013;18(1):64-72.

Hurria A, Akiba C, Kim J, et al. Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. Journal of oncology practice . 2016;12(12):e1025-e34.

Shahrokni A, Tin A, Downey RJ, et al. Electronic Rapid Fitness Assessment: A Novel Tool for Preoperative Evaluation of the Geriatric Oncology Patient. Journal of the National Comprehensive Cancer Network. 2017;15(2):172-9.

Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary. Journal of oncology practice. 2018;14(7):442-6.

FRancisco UoCS. ePrognosis 2018 [https://eprognosis.ucsf.edu/index.php]. Available from: https://eprognosis.ucsf.edu/index.php.

Liu D, Lehmann HP, Frick KD, et al. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. Journal of Urology. 2012;187(4):1241-6.

Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. Journal of the American Medical Association. 2005;293(17):2095-101.

Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. The New England journal of medicine. 2016;375(15):1415-24.

Scosyrev E, Messing EM, Mohile S, et al. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118(12):3062-70.

Briganti A, Spahn M, Joniau S, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. European Urology. 2013;63(4):693-701.

Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. The New England journal of medicine. 2014;370(10):932-42.

Joniau S, Gontero P, Briganti A, et al. 363 Stratification of high-risk prostate cancer into prognostic categories; a European multi-institutional study. The Journal of Urology. 2012;187(4S):e148-e9.

Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. The New England journal of medicine. 2002;346(15):1138-44.

Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. Journal of the American Medical Association. 2000;283(3):354-60.

Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. The Journal of urology. 2004;172(6 Part 1):2227-31.

Traboulsi SL, Nguyen DD, Zakaria AS, et al. Functional and perioperative outcomes in elderly men after robotic-assisted radical prostatectomy for prostate cancer. World journal of urology. 2020;38(11):2791-8.

Islamoglu E, Aksaray EE, Tas S, et al. Elderly Patients' Outcomes After Robot-Assisted Radical Prostatectomy: A Single Center Experience. Journal of laparoendoscopic & advanced surgical techniques. Part A. 2023;33(11):1097-101.

Haney CM, Kowalewski KF, Westhoff N, et al. Robot-assisted Versus Conventional Laparoscopic Radical Prostatectomy: A Systematic Review and Meta-analysis of Randomised Controlled Trials. European Urology Focus. 2023;9(6):930-7.

Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. The Journal of urology. 2004;172(6 Pt 1):2227-31.

Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology. 2016;17(8):1047-60.

Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology. 2016;17(8):1061-9.

Arcangeli G, Saracino B, Arcangeli S, et al. Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. Journal of clinical oncology. 2017;35(17):1891-7.

Catton CN, Lukka H, Gu CS, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of clinical oncology. 2017;35(17):1884-90.

Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of clinical oncology. 2016;34(20):2325-32.

Shahid N, Loblaw A, Chung HT, et al. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer. Clinical oncology : a journal of the Royal College of Radiologists. 2017;29(7):412-20.

Joseph N, Taylor C, O'Hara C, et al. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. Radiotherapy and oncology. 2016;121(2):299-303.

Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. International journal of radiation oncology, biology, physics. 2017;98(2):275-85.

Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. International journal of radiation oncology, biology, physics. 2017;98(2):286-95.

Rodda S, Morris WJ, Hamm J, et al. ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. International journal of radiation oncology, biology, physics. 2017;98(3):581-9.

Hoskin P, Rojas A, Ostler P, et al. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiotherapy and oncology. 2017;124(1):56-60.

D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Journal of the American Medical Association. 2008;299(3):289-95.

Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. The New England journal of medicine. 2011;365(2):107-18.

Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). European Urology. 2008;53(5):941-9.

Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24(12):1868-76.

Sun M, Choueiri TK, Hamnvik OP, et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncology. 2016;2(4):500-7.

Klotz L, O'Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. Journal of clinical oncology. 2015;33(10):1151-6.

Limonta P, Montagnani Marelli M, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert opinion on investigational drugs. 2001;10(4):709-20.

Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. The New England journal of medicine. 2013;368(14):1314-25.

Magnan S, Zarychanski R, Pilote L, et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Oncology. 2015;1(9):1261-9.

Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of clinical oncology. 2018;36(11):1080-7.

Gravis G, Boher JM, Joly F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European Urology. 2016;70(2):256-62.

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015;373(8):737-46.

James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77.

Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. The New England journal of medicine. 2017;377(4):352-60.

Chi KN, Protheroe A, Rodriguez-Antolin A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology. 2018;19(2):194-206.

James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. The New England journal of medicine. 2017;377(4):338-51.

Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of oncology. 2018;29(5):1235-48.

Wallis CJD, Klaassen Z, Bhindi B, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis. European Urology. 2018;73(6):834-44.

Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353-66.

Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. European Urology. 2009;55(6):1368-75.

Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2015;26 Suppl 5:v69-77.

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. The New England journal of medicine. 2019;381(2):121-31.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. Journal of clinical oncology. 2019;37(32):2974-86.

Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. The New England journal of medicine. 2019;381(1):13-24.

Aapro M, Saad F. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Therapeutic advances in urology. 2012;4(2):85-101.

Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2× 2 factorial design. The Lancet. 2022;399(10336):1695-707.

Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. Future oncology. 2022;18(21):2585-97.

Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(23):2197-206.

Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. The New England journal of medicine. 2018;378(15):1408-18.

Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. The New England journal of medicine. 2020;383(11):1040-9.

Saad F, Bogemann M, Suzuki K, et al. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate cancer and prostatic diseases. 2021;24(2):323-34.

Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology. 2008;26(2):242-5.

Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncology. 2013;14(2):117-24.

Oudard S, Fizazi K, Sengelov L, et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. Journal of clinical oncology. 2017;35(28):3189-97.

de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.

Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. Journal of clinical oncology. 2017;35(28):3198-206.

Climent MÁ, Pérez-Valderrama B, Mellado B, et al. Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. European Journal of Cancer. 2017;87:30-7.

Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology. 2012;13(10):983-92.

Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology. 2015;16(2):152-60.

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012;367(13):1187-97.

Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. European Urology. 2017;71(2):151-4.

Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncology. 2016;17(2):153-63.

Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Journal of clinical oncology. 2016;34(18):2098-106.

de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. The New England journal of medicine. 2020;382(22):2091-102.

Hussain M, Mateo J, Fizazi K, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. The New England journal of medicine. 2020;383(24):2345-57.

Abida W, Patnaik A, Campbell D, et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. Journal of clinical oncology. 2020;38(32):3763-72.

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine. 2010;363(5):411-22.

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of clinical oncology. 2020;38(1):1-10.

Abida W, Cheng ML, Armenia J, et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology. 2019;5(4):471-8.

Prior JO, Gillessen S, Wirth M, et al. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force. European journal of cancer. 2017;77:127-39.

Parker C, Zhan L, Cislo P, et al. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. European journal of cancer. 2017;71:1-6.

Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804.

Sun M, Cole AP, Hanna N, et al. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. The Journal of Urology. 2018;199(6):1417-25.

Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU International. 2013;111(4):543-8.